Astec Lifesciences Limited AI Stock Analysis
Want to see IN:ASTEC full AI Analyst Report?
Astec Lifesciences Limited (ASTEC) AI Stock Analysis
Astec Lifesciences Limited
(NSE:ASTEC)
The overall stock score is heavily weighed down by deep operational struggles and bearish market sentiment. Massive cash burn and an inability to generate positive earnings are the most significant risks, which are further compounded by strong negative technical momentum and a lack of valuation support.
Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 12.30B
- Dividend Yield
- ―
- Average Volume (3M)
- 11.82K
- Price to Earnings (P/E)
- -15.5
- Beta (1Y)
- 1.08
- Revenue Growth
- 16.06%
- EPS Growth
- 36.97%
- Country
- India
- Employees
- 471
- Sector
- General
- Sector Strength
- 55
- Industry
- Agricultural Inputs
Astec Lifesciences Limited Business Overview & Revenue Model
Company Description
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the co...
Astec Lifesciences Limited Financial Statement Overview
Summary
Astec Lifesciences is navigating severe financial distress characterized by chronic unprofitability and accelerating cash burn, with operating cash flow plunging to negative 1.12 billion. While the balance sheet saw vital deleveraging and a modest top-line recovery to 4.48 billion, core fundamentals remain deeply weak.
Income Statement
25NegativeBalance Sheet
45NeutralCash Flow
10Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.39B | 4.48B | 3.81B | 4.58B | 6.28B | 6.77B |
| Gross Profit | 686.74M | 419.01M | -685.16M | 1.33B | 2.27B | 2.86B |
| EBITDA | -46.13M | -15.49M | -662.07M | -2.69M | 893.14M | 1.65B |
| Net Income | -795.77M | -809.17M | -1.35B | -469.30M | 255.65M | 898.59M |
Balance Sheet | ||||||
| Total Assets | 7.94B | 9.42B | 8.81B | 9.75B | 9.79B | 8.97B |
| Cash, Cash Equivalents and Short-Term Investments | 22.82M | 122.51M | 8.55M | 16.47M | 27.54M | 33.44M |
| Total Debt | 3.31B | 4.49B | 5.55B | 4.94B | 3.41B | 2.79B |
| Total Liabilities | 4.59B | 5.51B | 6.46B | 6.05B | 5.60B | 5.00B |
| Stockholders Equity | 3.35B | 3.91B | 2.35B | 3.69B | 4.19B | 3.96B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.18B | -302.20M | -1.25B | -426.03M | -803.74M |
| Operating Cash Flow | 0 | -1.13B | -83.99M | 102.21M | 746.56M | 236.04M |
| Investing Cash Flow | 0 | -49.07M | -152.30M | -1.35B | -1.13B | -1.04B |
| Financing Cash Flow | 0 | 1.27B | 237.33M | 1.25B | 377.70M | 804.77M |
Astec Lifesciences Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 554.10 is below the 20-day moving average (MA) of 606.23, below the 50-day MA of 659.21, and below the 200-day MA of 660.78, indicating a bearish trend. The MACD of -40.01 indicates Positive momentum. The RSI at 35.86 is Neutral, neither overbought nor oversold. The STOCH value of 41.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.
Astec Lifesciences Limited Peers Comparison
Overall Rating
IN:DHANUKA73Outperform
IN:SHARDACROP71Outperform
IN:BHARATRAS67Neutral
IN:INSECTICID66Neutral
IN:IPL55Neutral
IN:ASTEC39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 40.27B | 14.56 | ― | 0.22% | -0.06% | 0.75% | |
| 71Outperform | INR 65.69B | 10.22 | ― | 2.06% | 17.28% | 42.45% | |
| 67Neutral | INR 17.52B | 7.75 | ― | 0.05% | -5.17% | 4.24% | |
| 66Neutral | INR 15.74B | 12.58 | ― | 0.92% | 1.26% | -16.43% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | INR 13.73B | 14.38 | ― | 0.63% | 2.89% | -9.47% | |
| 39Underperform | INR 12.33B | -15.54 | ― | ― | 16.06% | 36.97% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ASTEC | Astec Lifesciences Limited | 554.10 | -96.30 | -14.81% | |
| IN:BHARATRAS | Bharat Rasayan Limited | 981.00 | -1563.79 | -61.45% | |
| IN:DHANUKA | Dhanuka Agritech Limited | 895.40 | -339.02 | -27.46% | |
| IN:INSECTICID | Insecticides (India) Limited | 534.85 | -141.22 | -20.89% | |
| IN:IPL | India Pesticides Ltd. | 117.70 | -59.00 | -33.39% | |
| IN:SHARDACROP | Sharda Cropchem Ltd. | 721.90 | -37.53 | -4.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
